These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7934131)

  • 1. Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease.
    Sagayadan GE; Wiernik PH; Sun N; Ahearn G; Thompson D; Hallam SJ; Hu XP; Dutcher JP; Gallagher RE
    Leuk Res; 1994 Oct; 18(10):741-8. PubMed ID: 7934131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM.
    Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Leukemia; 2000 Aug; 14(8):1396-400. PubMed ID: 10942234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A differential sensitivity to recombinant human interferon-alpha 2a between normal and chronic myeloid leukaemic peripheral blood granulocyte-macrophage colony-forming units.
    Gronthos S; To LB; Haylock DN; Juttner CA
    Leuk Res; 1992; 16(2):153-8. PubMed ID: 1545568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
    Marley SB; Deininger MW; Davidson RJ; Goldman JM; Gordon MY
    Exp Hematol; 2000 May; 28(5):551-7. PubMed ID: 10812245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
    Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.
    Gordon MY; Marley SB; Lewis JL; Davidson RJ; Nguyen DX; Grand FH; Amos TA; Goldman JM
    J Clin Invest; 1998 Aug; 102(4):710-5. PubMed ID: 9710439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia.
    Zheng A; Savolainen ER; Koistinen P
    Leuk Res; 1996 Mar; 20(3):243-8. PubMed ID: 8637219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures.
    Robak T; Korycka A
    Leuk Lymphoma; 1996 Mar; 21(1-2):161-8. PubMed ID: 8907284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.
    Mahon FX; Chahine H; Barbot C; Pigeonnier V; Jazwiec B; Reiffers J; Ripoche J
    Leukemia; 1997 May; 11(5):667-73. PubMed ID: 9180290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
    Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
    Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth advantage of chronic myeloid leukemia CFU-GM in vitro: survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids +- alpha-interferon.
    Ferrero D; Foli C; Giaretta F; Argentino C; Rus C; Pileri A
    Leukemia; 2001 Mar; 15(3):422-9. PubMed ID: 11237066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow.
    Osterholz J; Dowding C; Guo AP; Siczkowski M; Goldman JM
    Exp Hematol; 1991 Jun; 19(5):326-31. PubMed ID: 2026184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
    Korycka A; Robak T
    Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
    Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C
    Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
    Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
    Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon.
    Pelus LM; Vadhan-Raj S
    Am J Hematol; 1988 May; 28(1):21-6. PubMed ID: 3130750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
    Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
    Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.